61 - Establishing Breakpoints for Resistance: Two Points of View

Speaker(s)

• 

  Christian Giske, MD, PhD

  Head of Clinical microbiology and immunology
  Karolinska Institutet
  Stockholm, Stockholms Lan, Sweden

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• TK

  Thomas Kirn, MD PhD

  Assoc. Professor
  Rutgers Robert Wood Johnson Medical School
  New Brunswick, New Jersey

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
ACPE Credits: ACPE 1.25 Knowledge-based contact hours of pharmacy CE
ACPE Number: 0221-9999-20-465-H04-P

Learning Objectives:

• differentiate between CLSI Intermediate (I) and Susceptible Dose Dependent (SDD) categorical interpretations
• describe relationship between antimicrobial exposure and susceptibility breakpoints and why setting breakpoints bisecting the wild-type population of a given species-antimicrobial combination should be avoided
• describe how should PK-PD targets be selected and what is a reasonable population target attainment in mathematical PK-PD simulations

Presentations:

• 10:00am – 11:15am EDT

  CLSI Perspective
  Thomas Kirn, MD PhD – Rutgers Robert Wood Johnson Medical School
• 10:00am – 11:15am EDT

  EUCAST Perspective
  Christian G. Giske, MD, PhD – Karolinska Institutet